Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Nov 20;40(33):3800-3807.
doi: 10.1200/JCO.21.02476. Epub 2022 Aug 23.

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study

Uwe Platzbecker  1 , Katharina S Götze  2 , Philipp Kiewe  3 , Ulrich Germing  4 , Karin Mayer  5 , Markus Radsak  6 , Thomas Wolff  7 , Joerg Chromik  8 , Katja Sockel  9 , Uta Oelschlägel  9 , Detlef Haase  10 , Thomas Illmer  11 , Haifa Kathrin Al-Ali  12   13 , Gerda Silling  14 , Joseph G Reynolds  15 , Xiaosha Zhang  15 , Kenneth M Attie  15 , Jeevan K Shetty  16 , Aristoteles Giagounidis  17
Affiliations
Clinical Trial

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study

Uwe Platzbecker et al. J Clin Oncol. .

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Luspatercept has high clinical activity in patients with transfusion-dependent lower-risk myelodysplastic syndromes (LR-MDS) and ring sideroblasts (RS) relapsed or refractory to erythropoietin. We report long-term luspatercept safety and efficacy in 108 patients with LR-MDS in the PACE-MDS study, including 44 non-RS and 34 non-transfusion-dependent or previously untreated patients. The primary end point was safety. Secondary end points included rates of hematologic improvement (HI) erythroid (HI-E), HI neutrophil, and HI platelet. Exploratory end points included erythropoiesis biomarker quantitation and mutation data. Median duration of luspatercept exposure was 315 days (range, 21-1,934 days). No new safety signals emerged. HI-E was observed in 53.7% of patients, including 36.4% of non-RS and 70.6% of non-transfusion-dependent patients. HI neutrophil and HI platelet were observed in 33.3% and 9.5% of patients, respectively. An almost three-fold increase in bone marrow late to early progenitor cell ratio accompanied HI-E response, irrespective of RS status. Lower baseline erythropoietin levels in non-RS patients (69.6 v 623.3 IU/L; P = .0077) and higher late to early erythroid progenitor cell ratio (10.44 v 4.48; P = .0106) in RS patients were associated with HI-E. This study highlights luspatercept's effects across LR-MDS subtypes, including untreated MDS-RS, serving as a platform for future trials.

Trial registration: ClinicalTrials.gov NCT01749514 NCT02268383.

PubMed Disclaimer

Conflict of interest statement

Uwe PlatzbeckerHonoraria: Celgene/Jazz, AbbVie, Curis, Geron, JanssenConsulting or Advisory Role: Celgene/Jazz, Novartis, BMS GmbH & Co KGResearch Funding: Amgen (Inst), Janssen (Inst), Novartis (Inst), BerGenBio (Inst), Celgene (Inst), Chris (Inst)Patents, Royalties, Other Intellectual Property: Part of a patent for a TFR-2 antibodyTravel, Accommodations, Expenses: Celgene Katharina S. GötzeHonoraria: BMSConsulting or Advisory Role: Celgene/BMS, AbbVie, Servier/PfizerResearch Funding: BMS Philipp KieweConsulting or Advisory Role: Roche, Bristol Myers Squibb/Celgene, BeiGene, Amgen, Pfizer, AstraZeneca/MerckSpeakers’ Bureau: Excellence in Oncology Ulrich GermingHonoraria: Celgene/BMS, Jazz Pharmaceuticals, NovartisConsulting or Advisory Role: CelgeneResearch Funding: Celgene (Inst), Novartis (Inst) Karin MayerStock and Other Ownership Interests: Roche Pharma AG, Autolus Therapeutics, Merck Serono, Pfizer, Gilead Sciences, BMSi Markus RadsakHonoraria: CelgeneConsulting or Advisory Role: Takeda, Novartis, CORAT Thomas WolffHonoraria: AstraZeneca, Apogepha, AbbVie, Incyte, SeaganConsulting or Advisory Role: Roche Katja SockelHonoraria: Bristol Myers Squibb/Celgene, Novartis, Alexion Pharmaceuticals, SOBIConsulting or Advisory Role: Takeda, NovartisTravel, Accommodations, Expenses: Jazz Pharmaceuticals, Celgene/Bristol Myers Squibb Detlef HaaseHonoraria: Novartis, Jazz Pharmaceuticals, Takeda, Celgene/Bristol Myers SquibbResearch Funding: Celgene/BMSDTravel, Accommodations, Expenses: Celgene/Bristol Myers Squibb Thomas IllmerConsulting or Advisory Role: Novartis, AstraZeneca, AbbVie Haifa Kathrin Al-AliHonoraria: Novartis, BMSi, Incyte (Inst), Takeda, Pfizer, AbbVieConsulting or Advisory Role: Novartis, BMSi, AbbVieResearch Funding: Novartis (Inst), BMSi (Inst), Incyte (Inst)Travel, Accommodations, Expenses: BMSi, Novartis Gerda SillingTravel, Accommodations, Expenses: AbbVie Joseph G. ReynoldsEmployment: Acceleron Pharma, Inc, C4 TherapeuticsStock and Other Ownership Interests: Acceleron Pharma, Inc Xiaosha ZhangEmployment: Acceleron Pharma, IncStock and Other Ownership Interests: Acceleron Pharma, Inc Kenneth M. AttieEmployment: Acceleron Pharma, Inc, ImaraLeadership: Imara Jeevan K. ShettyEmployment: Bristol Myers Squibb/CelgeneStock and Other Ownership Interests: Bristol Myers Squibb/Celgene Aristoteles GiagounidisStock and Other Ownership Interests: Novartis, RocheHonoraria: Amgen, Novartis, Bristol Myers Squibb/CelgeneConsulting or Advisory Role: Bristol Myers Squibb/CelgeneNo other potential conflicts of interest were reported.

References

    1. Adès L, Itzykson R, Fenaux P: Myelodysplastic syndromes. Lancet 383:2239-2252, 2014 - PubMed
    1. Malcovati L, Hellström-Lindberg E, Bowen D, et al. : Diagnosis and treatment of primary myelodysplastic syndromes in adults: Recommendations from the European LeukemiaNet. Blood 122:2943-2964, 2013 - PMC - PubMed
    1. Platzbecker U: Treatment of MDS. Blood 133:1096-1107, 2019 - PubMed
    1. Attie KM, Allison MJ, McClure T, et al. : A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol 89:766-770, 2014 - PMC - PubMed
    1. Suragani RN, Cadena SM, Cawley SM, et al. : Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 20:408-414, 2014 - PubMed

Publication types

MeSH terms

Associated data